Introduction
Molecular cytogenetic studies have revealed that, to a great extent, the clinical heterogeneity of multiple myeloma (MM) is dictated by the underlying genetic and cytogenetic aberrations present in the clonal plasma cells (PCs). This greater understanding has defined several molecular subtypes of myeloma characterized primarily by the presence of specific chromosome translocations and associated chromosome ploidy changes. [1] [2] [3] This characterization is also associated, and ratified, by the existence of specific transcription patterns that emerge from these cytogenetically defined categories. 4, 5 It is also clear that these major cytogenetic categories are already present in the early stages of the disease (i.e., MGUS), [6] [7] [8] and that additional genetic insults must participate in the progression to the more aggressive forms of the disease. Several candidate aberrations including deletions and mutations of p53, and mutations of ras have been associated with disease progression, but only for a small fraction of cases, and with yet to be proven pathogenic consequences. 1 Recently the group from the University of Arkansas (UAMS) identified strong prognostic associations with an increased level of gene expression of a cell cycle associated gene, CKS1B, located on chromosome 1q21. 9 ,10 CKS1B favors cell cycle progression by promoting degradation of p27 with release of the cyclin dependent kinases and entry into mitosis. 11, 12 This increased level of expression is associated with copy number gain of chromosome 1 at band q21 in a subset of patients. Subsequently, the same group showed that 1q21 copy gain by Fluorescent in situ hybridization (FISH) using a bacteria artificial chromosome (BAC) probe for CKS1B was also an important prognostic factor in MM patients entered into total therapy II. 13 Previously comparative genomic hybridization studies have shown that gains of chromosome 1q consistently involving the 1q21 region is one of the most common genetic abnormalities in MM. [14] [15] [16] Gain of 1q21 can occur as isochromosomes, duplications or jumping translocations in MM. 17, 18 Many of these chromosome changes are structural and do not involve copy number changes.
However, the association of 1q21 copy gain and expression with proliferation and recurrent genetic abnormalities, and their relative impact on survival have not been clearly established. In this study, we assessed gain of chromosome 1q21 by FISH and increase CKS1B gene expression by gene expression profiling (GEP), their relationship, prognostic impact and clinical and biologic correlations.
Patients and methods
Patient cohorts Group 1: Mayo Clinic patients treated with HDT studied by FISH. We studied a cohort of 159 patients treated at the Mayo Clinic that had been treated with melphalan-based highdose therapy (HDT). Patients were treated with melphalan at 200 mg/m 2 (n ¼ 63) or melphalan at 140 mg/m 2 plus total body irradiation (n ¼ 83), and other conditioning regimens in 13. Of these patients 89 (56%) had been transplanted at the time of relapse. Of the 159 patients 114 have died. Median and minimum follow-up of the 45 survivors is 55 and 43 months, respectively.
In all cases studied a research bone marrow (BM) sample had been obtained before HDT. All patients gave written informed consent for the collection and long-term storage of additional cells at the time of the BM examination including separate authorization for genetic studies and separate consent for review of their charts in accord with both federal regulations and Health Insurance Portability and Accountability Act (HIPAA) guidelines. The consent was approved by the Institutional Review Board of the Mayo Clinic College of Medicine. Cytospin slides were made in all cases and the remaining sample was purified using CD138 þ magnetic beads when possible and stored in liquid nitrogen for future use. All patients in whom available samples were obtained were used in this analysis.
Group 2: Mayo Clinic patients studied by GEP. Gene expression analysis was performed on CD138 þ selected PCs from pretreatment BM samples of 67 newly diagnosed MM patients using the Affymetrix U133A chip (Affymetrix, Santa Clara, CA, USA). This group of patients was subsequently treated with various forms of therapy including HDT and stem cell rescue in 63% (none of these patients are in group 1), melphalan-based oral chemotherapy in 21%, dexamethasonebased chemotherapy in 13% and novel agents in 3%.
Group 3: UAMS patients treated with HDT (Total Therapy II). These are newly diagnosed patients entered into Total Therapy II studies. These patients have FISH analysis for 1q21 copy number using the same probe as that used in our study, as well as GEP performed on CD138 þ selected PCs from pretreatment BMs using the Affymetrix U133plus chip. The FISH and GEP of these patients have been published. 13, 19 For our analysis we utilized a subset of patients (n ¼ 248) with both FISH and GEP results available (These data are available from the NIH Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/, under accession number GSE2658). These patients were assigned Translocations and Cyclin (TC) class and a gene expression-based proliferation index (PI) based on published methods. 4 
Methods

FISH. The cytoplasmic immunoglobulin light chain (cIg-FISH)
technique 20 that combined the interphase FISH strategy with fluorescent detection of cIg was used. For the detection of the common chromosome abnormalities (t(11;14)(q13;q32), t(4;14)(p16;q32), þ 14q32, chromosome 13 abnormalities (D13) and À17p13), we used the same probes and conditions published previously by us. 21 To score for 1q21 copy gain by FISH we used a BAC RPCI 11.C 307C12 whose insert contains CKS1B. This is the same probe used to show the prognostic importance of chromosome 1q21 gain in a recent study. 13 Briefly, the BAC was grown in selective media, DNA was extracted and directly labeled with a SpectrumGreen fluorophore by standard nick translation. The following PCR primers were designed to confirm the BAC DNA contained CKS1B, 5 0 -GGGCGTGGTTAGGGTACTGA-3 0 and 5 0 -AGCGCTACTCTCCTGTTAGGG-3 0 . The labeled probe was then tested on normal metaphases to reaffirm localization of the probe to chromosome 1 at band q21, and exclude cross hybridization. A commercially available chromosome enumeration probe (CEP) for the alpha satellite DNA of chromosome 1 labeled in SpectrumOrange (Vysis, Downer Grove, IL, USA) was used as ploidy control.
To ascertain for the presence of gene copy gain we used two different strategies. In the first, we use a methodology designed for the study of HER-2/neu. 22 In brief, 100 cells per sample were initially scored to determine concordance of signals derived from the CEP and the 1q21 probes. If the ratio was determined to be greater than 1, the results of 30 clonal cells were entered into a matrix to define the actual proportion of cells exhibiting a possible amplification or copy gain pattern, and determine a final ratio (Supplementary Figure 1) . A ratio greater than 1 represents copy gain of 1q21. This strategy will allow the assessment of the effect of 1q21 gain independent of ploidy changes. The second strategy is similar to that used by Hanamura et al., 13 where the absolute copy of 1q21 is counted. We considered patients who have three or more signals in more than 20% of cells counted as having gain of chromosome 1q21. One hundred cIg-positive cells were counted.
GEP
Gene expression analysis was performed on CD138 þ cells using the Affymetrix U133A chip (Affymetrix, Santa Clara, CA, USA). RNA isolation, purification and microarray hybridization has been reported previously. 23 Gene expression intensity values were log transformed, normalized to the median and analyzed using GeneSpring 7 (Agilent Technologies, Palo Alto, CA, USA).
Statistics
To describe the prevalence of abnormalities we used simple descriptive statistics. The Wilcoxon rank sum test was used to compare the difference in PC labeling index (PCLI) between patients with and without 1q21 copy change. Correlation between the level of CKS1B gene expression and the PCLI was assessed using the Pearson's correlation coefficient. The relationship between 1q21 copy change and CKS1B gene expression and cytogenetic categories was assessed by the w 2 test. Two-tailed p-values were reported with the significance level set at 0.05. Survival (overall and progression free) probabilities were determined using the methods of KaplanMeier. Cox proportional hazards models were used to assess the association of several prognostic factors with survival.
Results
Clinical features of patients studied for DNA copy gain A total of 159 patients, in whom we had stored research samples and had been treated with HDT and stem cell transplant between January 1990 and January 2001, were studied. The characteristics of these patients are given in Supplementary  Table 1 .
Prevalence of 1q21/CKS1B gain among patients in group 1
Using the ratio method, 46 (30%) of 159 patients studied had 1q21 gain (ratio41). The ratio between CKS1B and control probe was greater than 2.0 in only two cases and between 1.5 and 2.0 in 30 cases. When absolute copy number was used, 59 (37%) patients had 1q21 gain. The copy number ranges from 3 to 8 with the median being 5. The level of gene copy number change observed is much lower than that observed with true amplifications, such as c-myc in PC derived from patients with PC leukemia or the human MM cell lines (Figure 1 ) or for Her-2/ neu where the ratio and the absolute number of copy of the amplified gene are typically greater than 2.0 and 10, respectively. Therefore, we have decided to use copy number gain instead of amplification to describe the increase in 1q21 in this study.
Association of 1q21 gain and increased CKS1B expression with other genetic abnormalities (groups 1 and 3)
Of the 46 cases with 1q21 to CEP ratio greater than 1, most had determinations of D13, deletions of 17p13, t(11;14) and t(4;14) ( Table 1) . Patients with 1q21 copy number gain had a higher prevalence of D13 (33/46, 72%, P ¼ 0.007), and t(4;14) (13/45, 29%, w 2 P ¼ 0.001). In contrast these patients had a prevalence of t(11;14) as expected (6/45, 13%) and surprisingly a low or normal prevalence of p53 deletions (2/45, 4%). However, CKS1B gene expression level was similar between patients with spike expression of FGFR3/MMSET, CCND1, and MAF (normalized expression 1.8671.62 versus 1.6971.38 versus 2.587 1.88, analysis of variance P ¼ 0.28).
Chromosome 1q21 gain and elevated CKS1B gene expression was associated with more proliferative MM In patients studied by FISH (group 1), 1q21 gain (ratio41) was associated with higher PCLI, a validated marker of MM proliferation 24 (P ¼ 0.02). In patients studied by GEP (Group 2), level of CKS1B gene expression was correlated positively with the PCLI (Pearson coefficient, r ¼ 0.67, Po0.001).
Effects of 1q21 gain on overall survival (group 1)
The median survival of patients (n ¼ 159) with 1q21 gain (ratio41.0, n ¼ 46) was 29.9 months (95% confidence interval (CI) 16.4-40 months) versus 38 months (95% CI 28.7-50.4 months) for those with a normal ratio (n ¼ 113) (log-rank, ) as shown by dissociation between the CEP1 signal and the CKS1B probe.
Chromosome 1q21 copy change and prognosis in myeloma R Fonseca et al P ¼ 0.1224). When a more stringent cutoff ratio of 1.5 or greater was used, patients with elevated ratio (n ¼ 31) had a significantly shorter survival (median survival of 21.9 months (95% CI 13.6-37 months) versus 38 months (95% CI 29.8-50.4 months, logrank P ¼ 0.04) (Figure 2a) . However, when 1q21 gain was included in the multivariate model, it did not remain an independent prognostic factor as it was superseded by the negative prognostic effect of the t(4;14) and a higher PCLI (Table 2) . When an absolute increase in 1q21 copy regardless of chromosome 1 copy was used as the criterion, 1q21 gain is again significantly associated with reduced overall survival but was not an independent prognostic factor when included in a Cox proportional hazard analysis including PCLI and t(4;14) (data not shown).
Effects of increased CKS1B gene expression on survival (group 2)
Survival analysis was performed on the 67 patients with new diagnosis MM in whom gene expression data was available. Although this group of patients is small we hypothesized that a powerful prognostic factor would still be able to discern prognostic subgroups. When the groups were dichotomized by the median value of expression for CKS1B there was no difference in overall survival (P ¼ 0.13). When we applied a more stringent criterion (normalized CKS1B expression level 42.0), those having the high level of expression (n ¼ 12) had a significant shorter survival than those with lower levels (n ¼ 55): 12.8 months versus not yet reached (log-rank, P ¼ 0.007) (Figure 2b) . Interestingly, when we performed FISH in 23 of these patients who had materials for FISH studies, the 12 patients with 1q21 copy gain were enriched for cases with normalized CKS1B gene expression of greater than 2 (10 of 15 (67%) versus 2 of 8 (25%), P ¼ 0.05). In a multivariate analysis, limited by the low number of cases, and including only the following variables: PCLI greater than 1, 4p16 TC class and CKS1B expression greater than 2, only PCLI emerged as an independent prognostic factor.
Interactions between gain of 1q21 and increase CKS1B expression and their effect on survival (group 3) CKS1B expression increased with 1q21 copy number (Figure 3) . However, there was significant overlap in CKS1B gene expression between those with and without 1q21 copy gain. Using the median expression level (normalized expression of 1) as a cutoff for high expression level, 76 patients had gain of 1q21 and increase CKS1B expression, 44 patients had normal 1q21 but had CKS1B increased expression, 38 patients had gain of 1q21 but normal CKS1B gene expression and 126 patients had normal 1q21 and no increase in CKS1B expression. Interestingly, when the survival of patients with these combinations of 1q21 copy and CKS1B expression were compared, patients with increase 1q21 had the worst prognosis regardless of expression levels (Figure 2c) . In a multivariate Cox proportional hazard analysis including the following variables: gain of 1q21, increase CKS1B expression (above median), 4p16 TC class (corresponding to t (4;14)) and a PI based on median expression of 12 genes (this index correlated closely with PCLI; Patients with evidence of gain of 1q21 at a cut-off ratio of greater than 1.5 (n ¼ 31) have shorter survival than others (n ¼ 128) (log-rank P ¼ 0.042). (b) Kaplan-Meier analysis for overall survival according to the level of CKS1B gene expression (67 group two patients). Patients with normalized CKS1B expression level of greater than 2 (n ¼ 12) had significantly shorter survival than those with lower expression (median overall survival 13.1 months versus not yet reached, log-rank P ¼ 0.007). (c) Kaplan-Meier analysis for overall survival according to the both 1q21 copy gain and the level of CKS1B gene expression (248 group three patients). The survival of the four groups of patients was significantly different (log-rank P ¼ 0.03). On pair-wise comparisons, patients with copy number gain had similar survival irrespective of the level of expression. These patients had significantly worse survival than those with elevated gene expression alone. In turn, each of these prior groups had significant worse survival compared to patients with normal copy and expression. The limitation of this analysis is the relatively short follow-up such that of the four groups, only the median survival for those with increase copy and gene expression has been reached (49.4 months).
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Discussion
In this study, we show that gain of 1q21 is seen in about 30-37% of patients depending on the method of detection. Gain of 1q21 is also associated with t(4;14) and chromosome 13 deletion but not t (11;14) . This is consistent with the findings of a recently published study which showed that gain of 1q21 is associated with t(4;14) and MAF translocations, as well as chromosome 13 deletion but not with t (11;14) . 13 Interestingly, we do not see the same association between CKS1B gene expression and these primary IgH translocations. As expected, increase CKS1B expression is associated with more proliferative disease, as it is one of the genes associated with cell cycle activity and used by us to calculate the PI. We show for the first time that 1q21 copy gain is also associated with more proliferative disease.
Both 1q21 copy gain and increase CKS1B expression are associated with shortened survival in all three datasets analyzed. However, the net effect of these markers on survival seem to be modest and does not retain independence when entered into multivariate models that incorporates the high-risk cytogenetic categories of MM, particularly the t(4;14)(p16;q32), and proliferation markers. In the study by Hanamura et al., 13 gain of 1q21 emerged as an independent prognostic factor. However, in that study, proliferation markers and t(4;14) were not included in the multivariate analysis. Our analysis would suggest that possibly, the association between 1q21 gain and prognosis relates to its associations with other known high-risk factors such as the t(4;14) and PCLI.
One can think of four groups of patients according to 1q21 copy and CKS1B gene level status; no copy number change and no increased level of expression, copy number gain but no increased transcription, no copy number gain but increased gene expression and lastly increased copy number and increased level of expression. Indeed, one-third of patients from the UAMS dataset have discordant CKS1B copy number and expression. When the relative prognostic strength of 1q21 copy gain and increase CKS1B expression is analyzed in a multivariate model, 1q21 copy gain is the more significant prognostic factor.
There is evidence that 1q21 amplification is associated with disease progression in MM. 13, [25] [26] [27] Chromosome 1q21 abnormalities have also been associated with genomic instability in MM. Chromosome 1q21 gain may therefore be a marker of more clonally advance and genomically unstable tumor. Indeed patients with 1q21 gain without elevated CKS1B expression have equally poor survival as those with elevated CKS1B expression. In addition, the subsequent overexpression of candidate oncogenes or genes regulating cell cycle progression and proliferation, including CKS1B, located on the genome region of interest may explain the greater prognostic significance associated with 1q21 gain. Consistent with this, a large number Chromosome 1q21 copy change and prognosis in myeloma R Fonseca et al of candidate genes in the 1q21 region (e.g., BCL9, MCL1, CKS1B and MUC1) have been pathogenically implicated in MM and other malignancies. 9, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] More recently, integrated analysis of high-resolution array comparative genomic hybridization and GEP identified a high priority minimal region of DNA copy number change on 1q21. This 10 Mb region contain several genes including the aforementioned CSK1B, BCL9 and MCL1. 37 FISH detection of 1q21 gain may therefore provide more significant prognostic information. This strategy also indirectly tests the ability of surrounding genes to be associated with a negative outcome in MM.
In those cases with only increased CKS1B gene expression and no copy gain, the elevated gene expression is likely owing to downstream effects of other transcription factors that result in increased expression of a gene integral to the control of cell cycle, and is thus a proliferation marker.
In summary, our study shows that neither 1q21 gain as detected by FISH nor increased CKS1B expression are independent prognostic factors in MM and their impact on survival are probably mediated by their close associations with high-risk cytogenetic such as t (4;14) , and more proliferative disease. Chromosome 1q21 gain has a more significant impact on survival than increase CKS1B expression and probably reflects an underlying more clonally advance and genetically unstable tumor.
